Oncolytics Biotech Inc Stock Price, News & Analysis

Oncolytics Biotech announced key developments in their clinical trials, notably the full enrollment of the Phase 2 BRACELET-1 trial focused on HR+/HER2- breast cancer and success in the pancreatic cancer cohort of the GOBLET trial, achieving partial responses in all Phase 1b patients.

They reported $33.7 million in cash as of June 30, 2022, providing a financial runway into late 2023. The management highlighted pelareorep's potential to enhance cancer treatment outcomes. A conference call is scheduled today for further details.

Oncolytics Biotech (NASDAQ: ONCY) announced a conference call on August 11, 2022, at 8:30 a.m. ET to discuss Q2 financial results and corporate updates. Pelareorep, its lead therapeutic agent, is under evaluation in clinical trials targeting various cancers, including metastatic breast cancer. The company emphasizes the potential of pelareorep in enhancing immune responses and its synergy with other oncology treatments. However, risks such as funding availability and the efficacy of pelareorep may impact future outcomes.

Oncolytics Biotech has announced positive results from the phase 1b portion of its GOBLET study for pancreatic cancer, showing partial responses in all patients (n=3). The study evaluated pelareorep combined with chemotherapy and an anti-PD-L1 checkpoint inhibitor, meeting the criteria for expansion to additional patients. An independent review reported no toxicity concerns, suggesting potential for improved treatment approaches in pancreatic cancer, which has limited standard treatment efficacy. The findings will be featured at the ESMO World Congress on Gastrointestinal Cancer.

Oncolytics Biotech Inc. (NASDAQ: ONCY) held its Annual General Meeting (AGM) on June 16, 2022, with a shareholder turnout of 40.43%. James T. Parsons was elected to the Board of Directors, replacing Leonard Kruimer who did not seek re-election. Mr. Parsons, a seasoned executive with over 20 years in the life sciences sector, previously served as CFO at Trillium Therapeutics before its acquisition by Pfizer for $2.2 billion. The meeting also approved all resolutions, including the number of directors and the appointment of auditors for the upcoming year.

Oncolytics Biotech (NASDAQ: ONCY) has announced that Dr. Matt Coffey, President and CEO, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on May 18, 2022, at 11:00 a.m. ET. The conference will be held at the InterContinental New York Barclay. A live webcast of the presentation will be available on the company’s Investor Relations page and archived until August 15, 2022. Oncolytics is developing pelareorep, an immunotherapeutic agent aimed at treating various cancers.

Oncolytics Biotech announced key operational highlights and financial results for Q1 2022, with a cash position of $39.5 million expected to fund upcoming milestones. The company reported positive clinical data for its lead drug, pelareorep, showing improved patient outcomes in HR+/HER2- breast cancer and successful combinations with CAR T therapies in preclinical studies. Operating expenses decreased from $3.1 million to $2.6 million year-over-year, though net loss increased to $6.8 million. Upcoming milestones include data from the BRACELET-1 study in Q4 2022.

On May 4, 2022, Oncolytics Biotech announced favorable results from its AWARE-1 study on pelareorep for HR+/HER2- breast cancer. The treatment demonstrated a 100% favorable Risk of Recurrence Score (ROR-S) in evaluable patients, up from 55% at baseline. Increases in tumor cell death markers and T cell activation were also noted. The study's findings support pelareorep's potential to enhance clinical outcomes by transforming tumors into less aggressive types. Future clinical trials, including BRACELET-1, aim to further evaluate its effectiveness.

Oncolytics Biotech Inc. (NASDAQ: ONCY) has announced that its abstract, detailing results from the AWARE-1 study, has been accepted for presentation at the European Society for Medical Oncology Breast Cancer Meeting from May 3-5, 2022, in Berlin. The study evaluated the oncolytic virus pelareorep combined with letrozole and atezolizumab in early-stage breast cancer patients. Results suggest pelareorep may enhance immune responses and improve treatment outcomes. The presentation is scheduled for May 4, 2022, at 12:15 p.m. CET, focusing on innovative cancer therapies.

Oncolytics Biotech Inc. (NASDAQ: ONCY) will host a conference call and webcast on May 5, 2022, at 5:00 p.m. ET to discuss its first-quarter financial results and corporate update. Pelareorep, an immunotherapeutic agent being developed by Oncolytics, is under evaluation for its efficacy in treating various cancers. The company is moving towards a registration study for metastatic breast cancer and is conducting clinical trials in combination with other therapies. Investors can access the webcast via the Investor Relations page on Oncolytics' website.